Fundz

Zymeworks Inc. reported raising $61.5 Million in an initial SEC Form D filing, from an offering of $75 Million

PUBLIC · ZYMEJan 21, 2016$61.5M of $75M raised

Amount Raised

$61.5 Million

$61.5 Million sold, per SEC Form D (first sale Jan 21, 2016)

Round Type

Venture

MiddletownBiotechnology

Quick answer

Zymeworks raised $61.5 Million in a funding round, dated January 21, 2016. Zymeworks is based in Middletown, Delaware, United States.

How much did Zymeworks raise?
Zymeworks raised $61.5 Million in a funding round on January 21, 2016.
What does Zymeworks do?
Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics.
Where is Zymeworks based and how big is it?
Zymeworks is based in Middletown, Delaware, United States. Fundz records about 300 employees.
Who are the decision-makers at Zymeworks?
Fundz holds 2 contacts at Zymeworks. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as Zymeworks that raised within 45 days of this round, from Fundz verified event records.

  • Kalera Medical, Inc. raised an undisclosed amount on March 4, 2016.
  • Ashvattha Therapeutics, LLC raised $300K (Seed) on March 4, 2016.
  • ZSX Medical, LLC raised $674K (Seed) on March 4, 2016.
  • Strata Oncology raised $6.3M on March 4, 2016.
  • Neurovance, Inc. raised $1M (Seed) on March 2, 2016.
  • USBC raised $1 on March 2, 2016.

Who to call at Zymeworks, and when

A new round usually means Zymeworks is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Zymeworks raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Zymeworks, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Zymeworks. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Zymeworks

Location

114 E 4th Avenue, Suite 800

Middletown, Delaware, United States

About

Zymeworks Inc. (Nasdaq: ZYME) is a global biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference for people impacted by difficult-to-treat cancers and other serious diseases. Zymeworks' complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using Zymeworks' proprietary AzymetricTM technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercialize zanidatamab in different territories. Zanidatamab is currently being evaluated in global Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials as a treatment for patients with HER2-expressing cancers. Zymeworks' next clinical candidate, zanidatamab zovodotin (ZW49), is a HER2-targeted bispecific antibody-drug conjugate (ADC) developed using Zymeworks' proprietary AzymetricTM and ZymeLinkTM Auristatin technologies. Zanidatamab zovodotin is being evaluated in a Phase 2 clinical trial for patients with HER2-expressing non-small cell lung cancer. Zymeworks is also advancing a deep pipeline of product candidates based on its experience and capabilities in both ADC and multispecific antibodies (MSAT), including planned IND filings for ZW171 and ZW191 in 2024. In addition to Zymeworks' wholly owned pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Zymeworks raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contacts12 people are listed at Zymeworks. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Zymeworks's next move

See what Strategic adds

Zymeworks raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.